Lonza Group AG 2018 AR2
The report outlines Lonza's financial and operational performance for the fiscal year 2018, highlighting a 9% organic sales growth and the successful integration of Capsugel. It details the company's strategic focus on the Healthcare Continuum across its Pharma & Biotech and Specialty Ingredients segments. The report also highlights Lonza's commitment to sustainability, including its "Vision Zero" initiative to reduce incidents, emissions, water consumption, and waste. Additionally, it notes key milestones such as the expansion of Ibex Solutions in Visp and the opening of the world's largest cell- and gene-therapy facility in Houston.
Company: Lonza Group AG
Sector: Manufacturing
Country: Switzerland
Year: 2018
Type: AR2
Pages: 340
Back to company
Lonza Group AG
Annual Report
The report outlines Lonza's financial and operational performance for the fiscal year 2018, highlighting a 9% organic sales growth and the successful integration of Capsugel. It details the company's strategic focus on the Healthcare Continuum across its Pharma & Biotech and Specialty Ingredients segments. The report also highlights Lonza's commitment to sustainability, including its "Vision Zero" initiative to reduce incidents, emissions, water consumption, and waste. Additionally, it notes key milestones such as the expansion of Ibex Solutions in Visp and the opening of the world's largest cell- and gene-therapy facility in Houston.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees